Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00711191 · ClinicalTrials.gov registry record · Phase 1
A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT00711191 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 22 participants.
The verdict
NCT00711191, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study aims to seek evidence that activation of certain cells of the immune system will be safe and well tolerated in combination with cytotoxic chemotherapy. Preliminary evidence of clinical anti-tumor activity will be sought.
Interventions
- DRUG chemotherapy
- BIOLOGICAL monoclonal antibody
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2008-06 |
| Est. Completion | 2011-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00711191
The ClinicalTrials.gov registry entry for NCT00711191 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which chemotherapy is the first listed.
NCT00711191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00711191 about?
NCT00711191 is a clinical study titled "A Study On An Immunostimulant Antibody In Combination With Chemotherapy For Advanced Cancer Of The Pancreas". This study aims to seek evidence that activation of certain cells of the immune system will be safe and well tolerated in combination with cytotoxic chemotherapy. Preliminary evidence of clinical anti-tumor activity will be sought.
What is the current status of trial NCT00711191?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2008-06. Estimated completion is 2011-01.
What interventions are being tested in trial NCT00711191?
The interventions under investigation include: chemotherapy (DRUG), monoclonal antibody (BIOLOGICAL).
Who is sponsoring clinical trial NCT00711191?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.